CSM Advisors’s Gilead Sciences GILD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.36M Buy
31,262
+20,457
+189% +$2.86M 0.11% 217
2025
Q4
$1.33M Sell
10,805
-4,270
-28% -$519K 0.04% 311
2025
Q3
$1.67M Sell
15,075
-42,400
-74% -$4.82M 0.05% 312
2025
Q2
$6.37M Sell
57,475
-780
-1% -$83K 0.19% 131
2025
Q1
$6.53M Sell
58,255
-750
-1% -$77.4K 0.36% 66
2024
Q4
$5.45M Sell
59,005
-4,760
-7% -$429K 0.25% 73
2024
Q3
$5.34M Sell
63,765
-3,200
-5% -$244K 0.35% 77
2024
Q2
$4.59M Sell
66,965
-1,310
-2% -$87.4K 0.32% 71
2024
Q1
$5M Sell
68,275
-1,350
-2% -$104K 0.33% 76
2023
Q4
$5.64M Sell
69,625
-995
-1% -$77.4K 0.41% 71
2023
Q3
$5.29M Sell
70,620
-2,995
-4% -$230K 0.46% 65
2023
Q2
$5.67M Sell
73,615
-1,150
-2% -$91.7K 0.43% 69
2023
Q1
$6.2M Hold
74,765
0.54% 54
2022
Q4
$6.42M Sell
74,765
-1,960
-3% -$155K 0.61% 49
2022
Q3
$4.73M Sell
76,725
-20,255
-21% -$1.28M 0.52% 60
2022
Q2
$6M Sell
96,980
-10
-0% -$619 0.55% 57
2022
Q1
$5.77M Sell
96,990
-9,400
-9% -$601K 0.39% 68
2021
Q4
$7.73M Sell
106,390
-3,520
-3% -$242K 0.51% 58
2021
Q3
$7.68M Hold
109,910
0.57% 52
2021
Q2
$7.57M Sell
109,910
-5,280
-5% -$353K 0.5% 56
2021
Q1
$7.45M Buy
+115,190
New +$7.43M 1.05% 40

Other funds holding GILD

CSM Advisors's GILD Position: Q1 2026 in Review

CSM Advisors increased its Gilead Sciences (GILD) stake by 189% in Q1 2026, buying an estimated $2.86M and bringing the position to 31,262 shares worth $4.36M. The position accounts for 0.11% of the portfolio, ranked #217.

CSM Advisors first reported a position in GILD in Q1 2021 and has held it in 21 quarters since. The position peaked at $7.73M in Q4 2021. 2,309 funds tracked by Wall St. Rank hold GILD as of Q1 2026.

  • CSM Advisors held 31,262 shares of Gilead Sciences worth $4.36M as of Q1 2026.
  • CSM Advisors bought 20,457 Gilead Sciences shares in Q1 2026, an estimated $2.86M.
  • Gilead Sciences made up 0.11% of CSM Advisors's portfolio in Q1 2026, its #217 holding.
  • CSM Advisors first reported a position in Gilead Sciences in Q1 2021 and has held it in 21 quarters since.
  • CSM Advisors's Gilead Sciences position peaked at $7.73M in Q4 2021.
  • 2,309 funds tracked by Wall St. Rank held Gilead Sciences as of Q1 2026.

Based on CSM Advisors's 13F filing for Q1 2026, filed 15 May 2026.